Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors in the central nervous program, conolidine modulates alternate molecular targets. A Science Advancements analyze identified that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabil... https://michaelt097tuu5.blogunok.com/profile